Journal of Biomedical and Clinical Research 17(2): 167-176, doi: 10.3897/jbcr.e125424
Antioxidant status in patients with hyperplasia and prostate cancer
expand article infoTeodora M. Velkovska‡, Adelaida L. Ruseva§
‡ UMHAT "St. Marina", Pleven, Bulgaria§ Medical University – Pleven, Pleven, Bulgaria

Corresponding author: Teodora M. Velkovska ( teodora.velkovska@yahoo.com )

Academic editor: Vladislav Dunev
© Teodora M. Velkovska, Adelaida L. Ruseva.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation: Velkovska TM, Ruseva AL (2024) Antioxidant status in patients with hyperplasia and prostate cancer. Journal of Biomedical and Clinical Research 17(2): 167-176. https://doi.org/10.3897/jbcr.e125424
Open Access
Abstract
This review aims to briefly describe and summarize data from various studies on the role and the link between serum Total Antioxidant Status (TAS) levels in patients with BPH and PC, as well as other more widely available endogenous antioxidants, the levels of markers of inflammation (CRP, Leuc.), as well as the link between the values of endogenous antioxidants and various harmful factors. Their levels and adequate assessment could help in the proper management of patients with BPH and PC, as well as in reducing morbidity.
Keywords
Antioxidant status, inflammation, oncological diseases, oxidative stress, prostate cancer, prostatic hyperplasia